Customize your JAMA Network experience by selecting one or more topics from the list below.
Degarelix, an advanced prostate cancer drug, rapidly reduced the risk of committing child sexual abuse among men with pedophilic disorder, a phase 2 trial in JAMA Psychiatry found.
The study involved 52 men in Sweden who were diagnosed with and seeking treatment for pedophilic disorder. They were randomly assigned to receive either 2 subcutaneous injections of degarelix acetate or a placebo.
At 2 weeks, the composite risk score of 5 domains of child sexual abuse (range, 0-15 points) decreased from 7.4 to 4.4 among participants in the degarelix group and from 7.8 to 6.6 in the placebo group. A decrease in risk score was also seen at 10 weeks in the treatment group.
Degarelix is a gonadotropin-releasing hormone antagonist that decreases testosterone to castration levels within 3 days without initial testosterone flare-ups seen with similar drugs. With further study, the fast-acting drug plus psychosocial support may be suitable for long-term treatment, the authors noted.
Slomski A. Prostate Cancer Drug Degarelix Rapidly Treats Pedophilic Disorder. JAMA. 2020;323(24):2453. doi:10.1001/jama.2020.10336
Coronavirus Resource Center
Create a personal account or sign in to: